To Get Help Now
Click Here
Today's Date:

Darvocet, Darvon Multidistrict Litigation Consolidation Deferred

AddThis Social Bookmark Button

A decision by a panel of federal judges on whether to consolidate all federal Darvocet lawsuits and Darvon lawsuits has been deferred until further arguments are heard later this year.

Though at the time of the request to consolidate there were only four lawsuits filed in federal court against Xanodyne Pharmaceuticals and Eli Lilly & Co., manufacturers of Darvocet and Darvon medications, lawyers expect thousands of cases to be filed by former users, who suffered heart arrhythmia or sudden cardiac related death due to the side effects of the painkillers.

Both manufacturers oppose the centralization of the Darvocet and Darvon cases, saying that evidence and discovery will need to focus on the health of the individual user. They also argued that a number of the plaintiffs may have taken generic forms of the drugs, manufactured by other companies.

Thus far, at least 18 lawsuits have been made against more than 12 different drug manufacturers or distributors.

The FDA sought the removal of name brand and generic medications that contained the ingredient propoxyphene, “ after receiving new clinical data showing that the drug puts patients at risk of potentially serious or even fatal heart rhythm abnormalities…. even when taken at recommended doses, propoxyphene causes significant changes to the electrical activity of the heart. These changes, which can be seen on an electrocardiogram (ECG), can increase the risk for serious abnormal heart rhythms that have been linked to serious adverse effects, including sudden death” and that the risk “of adverse events for any particular patient (even patients who have taken the drug for many years) is subject to change based on small changes in the health status of the patient, such as dehydration, a change in medications, or decreased kidney function. As a result of these data, combined with other information, including new epidemiological data, the agency concluded that the risks of the medication outweigh the benefits.” disclaimer: This article: Darvocet, Darvon Multidistrict Litigation Consolidation Deferred was posted on Friday, May 6th, 2011 at 6:52 pm at and is filed under Defective Drug Lawsuits.

« »

Leave a Reply

You must be logged in to post a comment.